Meta-analysis finds increased VTE risk in pediatric IBD, especially ulcerative colitis
Kids with Bowel Disease Face a Hidden Blood Clot Risk Adults Miss
A systematic review and meta-analysis of over 100,000 children and teenagers with IBD found a significantly increased risk of venous thrombo…
Children with Crohn's or ulcerative colitis face nearly seven times the blood clot risk of healthy kids, yet prevention guidelines for teens…
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk.
Does having a C-section raise your child's risk of inflammatory bowel disease?
This systematic review and meta-analysis evaluated the association between mode of delivery and risk of inflammatory bowel disease (IBD) in …
A review of over 13 million births found no link between C-sections and inflammatory bowel disease, easing concerns for parents.
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…